机构名称：
¥ 1.0
初始应用 - 仅根据医学肿瘤学家的建议，仅来自医学肿瘤学家或任何相关从业者的非小细胞肺癌一线单药治疗应用。批准有效期为4个月。Prerequisites (tick boxes where appropriate) □ Patient has locally advanced or metastatic, unresectable, non-small cell lung cancer and □ Patient has not had chemotherapy for their disease in the palliative setting and □ Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC and □ For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR or ALK tyrosine kinase unless not possible to ascertain and □ Pembrolizumab to be used as monotherapy and □ There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 50% as determined by a validated test unless not possible to ascertain or □ There is documentation confirming the disease expresses PD-L1 at a level greater than or equal to 1% as determined by a validated test unless not possible to ascertain and □根据临床医生评估，化学疗法被确定为患者的最大利益
特别授权-Pembrolizumab
主要关键词
相关文件推荐
